Document is current

Article History

Received: 26 June 2020

Revised: 14 December 2020

Accepted: 21 December 2020

First Online: 18 January 2021

Compliance with ethical standards

:

: HLM has received reimbursement of participation fees for scientific meetings and continuing medical education events from the following companies: Ferring, Lilly, Pfizer, Sandoz/Hexal, Novo Nordisk, IPSEN, and Merck Serono. He has received reimbursement of travel expenses from IPSEN and lecture honoraria from Pfizer. The other authors declare that they have no conflict of interest.

: All procedures performed in our study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The studies KRANIOPHARYNGEOM 2000 (clinical trial registration number: NCT00258453) and KRANIOPHARYNGEOM 2007 (clinical trial registration number: NCT01272622) were approved by the local standing-committee on ethical practice of the Medizinische Fakultät, Julius-Maximilians-Universität Würzburg, Germany (140/99; 94/06, respectively). Our study was approved by the ethical committee of the Carl von Ossietzky University Oldenburg, Germany (004/2015).

: Written parental and/or patient consent was obtained from all individual participants included in the study.

: Consent for publication was obtained from all participants

: Not available.